PMID- 28295527 OWN - NLM STAT- MEDLINE DCOM- 20170724 LR - 20220311 IS - 1096-8652 (Electronic) IS - 0361-8609 (Linking) VI - 92 IP - 6 DP - 2017 Jun TI - Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma. PG - 529-535 LID - 10.1002/ajh.24714 [doi] AB - We hereby report the clinical and biologic features of 33 of 4680 (0.7%) patients with chronic lymphocytic leukemia (CLL), managed at 10 Italian centers, who developed Hodgkin lymphoma (HL), a rare variant of Richter syndrome. The median age at CLL and at HL diagnosis were 61 years (range 41-80) and 70 years (range 46-82), respectively, with a median interval from CLL to the diagnosis of HL of 90 months (range 0-258). In 3 cases, CLL and HL were diagnosed simultaneously. Hl was characterized by advanced stage in 79% of cases, International Prognostic Score (IPS) >/=4 in 50%, extranodal involvement in 39%, B symptoms in 70%. Prior treatment for CLL had been received by 82% of patients and included fludarabine in 67%. Coexistence of CLL and HL was detected in the same bioptic tissue in 87% of cases. The most common administered treatment was the ABVD regimen given to 22 patients (66.6%). The complete response (CR) rate after ABVD was 68%, and was influenced by the IPS (P = .03) and interval from the last CLL treatment (P = .057). Survival from HL was also influenced by the IPS (P = .006) and time from the last CLL treatment (P = .047). The achievement of CR with ABVD was the only significant and independent factor predicting survival (P = .037). Taken together, our results show that the IPS and the interval from the prior CLL treatment influence the likelihood of achieving CR after ABVD, which is the most important factor predicting survival of patients with CLL developing HL. CI - (c) 2017 Wiley Periodicals, Inc. FAU - Mauro, Francesca Romana AU - Mauro FR AUID- ORCID: 0000-0003-2425-9474 AD - Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Policlinico Umberto I, Rome. FAU - Galieni, Piero AU - Galieni P AD - U.O.C. Ematologia e Trapianto di Cellule Staminali Emopoietiche, Ospedale Mazzoni, Ascoli Piceno. FAU - Tedeschi, Alessandra AU - Tedeschi A AD - Department of Hematology, Niguarda Cancer Center, Milan. FAU - Laurenti, Luca AU - Laurenti L AD - Department of Hematology, Catholic University, Rome. FAU - Del Poeta, Giovanni AU - Del Poeta G AD - Hematology, Dipartimento di Biomedicina e Prevenzione, Universita degli Studi di Roma Tor Vergata, Rome. FAU - Reda, Gianluigi AU - Reda G AD - Oncohematology Department, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan. FAU - Motta, Marina AU - Motta M AD - Department of Hematology, ASST Spedali Civili, Brescia. FAU - Gozzetti, Alessandro AU - Gozzetti A AD - Division of Hematology, University of Siena, Siena. FAU - Murru, Roberta AU - Murru R AD - UO Ematologia e CTMO Ospedale Oncologico A. Businco, Cagliari. FAU - Caputo, Maria Denise AU - Caputo MD AD - Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Policlinico Umberto I, Rome. FAU - Campanelli, Melissa AU - Campanelli M AD - Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Policlinico Umberto I, Rome. FAU - Frustaci, Anna Maria AU - Frustaci AM AD - Department of Hematology, Niguarda Cancer Center, Milan. FAU - Innocenti, Idanna AU - Innocenti I AD - Department of Hematology, Catholic University, Rome. FAU - Raponi, Sara AU - Raponi S AD - Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Policlinico Umberto I, Rome. FAU - Guarini, Anna AU - Guarini A AD - Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Policlinico Umberto I, Rome. FAU - Morabito, Fortunato AU - Morabito F AD - Hematology Section, Cosenza Hospital, Cosenza, Italy. FAU - Foa, Robin AU - Foa R AD - Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Policlinico Umberto I, Rome. FAU - Gentile, Massimo AU - Gentile M AD - Hematology Section, Cosenza Hospital, Cosenza, Italy. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20170418 PL - United States TA - Am J Hematol JT - American journal of hematology JID - 7610369 RN - 0 (Immunoglobulin Heavy Chains) RN - 11056-06-7 (Bleomycin) RN - 5V9KLZ54CY (Vinblastine) RN - 7GR28W0FJI (Dacarbazine) RN - 80168379AG (Doxorubicin) RN - ABVD protocol SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Bleomycin/therapeutic use MH - Combined Modality Therapy/adverse effects/methods MH - Dacarbazine/therapeutic use MH - Doxorubicin/therapeutic use MH - Female MH - Hodgkin Disease/diagnosis/drug therapy/*etiology/mortality MH - Humans MH - Immunoglobulin Heavy Chains/genetics MH - Leukemia, Lymphocytic, Chronic, B-Cell/genetics/*mortality/*pathology/therapy MH - Male MH - Middle Aged MH - Mutation MH - Neoplasms, Second Primary/diagnosis/drug therapy/*etiology/mortality MH - Prognosis MH - Remission Induction MH - Retrospective Studies MH - Risk Factors MH - Treatment Outcome MH - Vinblastine/therapeutic use EDAT- 2017/03/16 06:00 MHDA- 2017/07/25 06:00 CRDT- 2017/03/16 06:00 PHST- 2017/02/23 00:00 [received] PHST- 2017/02/28 00:00 [revised] PHST- 2017/03/06 00:00 [accepted] PHST- 2017/03/16 06:00 [pubmed] PHST- 2017/07/25 06:00 [medline] PHST- 2017/03/16 06:00 [entrez] AID - 10.1002/ajh.24714 [doi] PST - ppublish SO - Am J Hematol. 2017 Jun;92(6):529-535. doi: 10.1002/ajh.24714. Epub 2017 Apr 18.